

PRIOR AUTHORIZATION REQUEST FORM EOC ID:

Dupixent (dupilumab)

Phone: 800-728-7947 Fax back to: 866-880-4532

The Scott & White Health Plan Pharmacy Department manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name: Supervising Physician:	
Member/Subscriber Number:	Fax:	Phone:
Date of Birth:	Office Contact:	
Group Number:	NPI:	State Lic ID:
Address:	Address:	
City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name (if applicable):
Drug Name and Strength: Directions / SIG:		
Please attach any pertinent medical history or information following qu	for this patient that may support a estions and sign.	pproval. Please answer the
Q1. What is the prescriber's specialty? Allergy Dermatology Immunology Other (please specify)		
Q2. Please provide ICD code(s) for diagnosis.		
Q3. Is the patient a new start to Dupixent? Yes No - patient has been stable on Dupixent for less than No - patient has been stable on Dupixent for 16 weeks		
Q4. Is the patient 18 years or older?		
Q5. Does the patient have moderate to severe atopic derm area (BSA)?	natitis affecting greater than or equ	ual to 10% of body surface



PRIOR AUTHORIZATION REQUEST FORM EOC ID:

Dupixent (dupilumab)

Phone: 800-728-7947 Fax back to: 866-880-4532

The Scott & White Health Plan Pharmacy Department manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name: Supervising Physician:			
☐ Yes ☐ No				
Q6. Does the patient have failure of or contraindication to a apply One topical calcineurin inhibitor (ex. tacrolimus or El One medium to super high potency topical corticoste Eucrisa Other (Please Specify)				
Q7. Does the patient have failure of or contraindication to phototherapy ?				
☐ Yes ☐ No				
Q8. Does the patient have failure of or contraindication to a mofetil? ☐ Yes ☐ No	azathioprine, cyclosporine, methotrexate, OR mycophenolate			
Q9. For continuation of Dupixent, does the patient have a creduction in body surface area involvement, reduction in property. Yes No				
Q10. Additional Comments				
Q11. How will drug be billed?				
☐ Pharmacy claim (drug to be billed as a PHARMACY be to this specific member)	enefit claim and dispensed by pharmacy directly to member) enefit claim, but shipped direct to provider to be administered MEDICAL benefit claim as an expense to the provider, and			
Q12. If billing as a MEDICAL claim, what provider will be ling reimbursement)? Provide Name and NPI	nked to the claim (i.e. who is the billing entity seeking			
☐ Individual prescriber ☐ Provider or specialty group ☐ Facility				



PRIOR AUTHORIZATION REQUEST FORM EOC ID: Dupixent (dupilumab)

Phone: 800-728-7947 Fax back to: 866-880-4532

The Scott & White Health Plan Pharmacy Department manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:		Prescriber Name: Supervising Physician:	
	Prescriber Signature	Date	
E 19 1/11	A. Donaha akina dhila kan and aka	sing above. Learlify that applying the standard review timeframe m	

□ Expedited/Urgent - By checking this box and signing above, I certify that applying the standard review timeframe may seriously jeopardize the life or health of the enrollee or the enrollee's ability to regain maximum function

Lack of the necessary documentation may result in a medical necessity denial. Requesting providers may speak to a SWHP pharmacist or medical director at 1-800-728-7947 regarding the case to have an opportunity to help impact the decision on a request before coverage has been decided.

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document